1. Clinical Response to Donepezil in Mild and Moderate Dementia: Relationship to Drug Plasma Concentration and CYP2D6 and APOE Genetic Polymorphisms.
- Author
-
Miranda LF, Gomes KB, Tito PA, Silveira JN, Pianetti GA, Byrro RM, Peles PR, Pereira FH, Santos TR, Assini AG, Ribeiro VV, Moraes EN, and Caramelli P
- Subjects
- Chromatography, High Pressure Liquid, Donepezil, Female, Follow-Up Studies, Humans, Male, Mental Status and Dementia Tests, Neuropsychological Tests, Time Factors, Apolipoproteins E genetics, Cholinesterase Inhibitors blood, Cholinesterase Inhibitors therapeutic use, Cytochrome P-450 CYP2D6 genetics, Dementia blood, Dementia drug therapy, Dementia genetics, Indans blood, Indans therapeutic use, Piperidines blood, Piperidines therapeutic use, Polymorphism, Single Nucleotide genetics
- Abstract
The clinical response to donepezil in patients with mild and moderate dementia was investigated in relation to the drug plasma concentration and APOE and CYP2D6 polymorphisms. In a prospective naturalistic observational study, 42 patients with Alzheimer's disease (AD) and AD with cerebrovascular disease who took donepezil (10 mg) for 12 months were evaluated. Their DNA was genotyped, and the donepezil plasma concentrations were measured after 3, 6, and 12 months. Good responders scored ≥-1 on the Mini-Mental State Examination at 12 months in comparison to the baseline score. The study results indicated the good response pattern was influenced by the concentration of donepezil, but not by APOE and CYP2D6 polymorphisms.
- Published
- 2017
- Full Text
- View/download PDF